Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02058160
Registration number
NCT02058160
Ethics application status
Date submitted
6/02/2014
Date registered
7/02/2014
Date last updated
9/05/2017
Titles & IDs
Public title
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes
Query!
Scientific title
A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)
Query!
Secondary ID [1]
0
0
2013-003132-79
Query!
Secondary ID [2]
0
0
EFC12405
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
LixiLan-L
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Type 2 Diabetes
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Insulin glargine/lixisenatide (HOE901/AVE0010)
Treatment: Drugs - Insulin glargine (HOE901)
Treatment: Drugs - Metformin (Background Drug)
Experimental: Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) - FRC once daily (QD) for 30 weeks. Dose individually adjusted.
Active Comparator: Insulin glargine - Insulin glargine 100 U/mL QD for 30 weeks. Dose individually adjusted.
Treatment: Drugs: Insulin glargine/lixisenatide (HOE901/AVE0010)
Insulin glargine/lixisenatide FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using one of 2 SoloStar® pen-injectors: Pen A (ratio of 2 Units (U) of insulin glargine U 100:1 mcg of lixisenatide) or Pen B (ratio of 3 U of insulin glargine U 100:1 mcg of lixisenatide). After run-in, the FRC was initiated at a dose of either 20 U/10 mcg with Pen A or 30 U/10 mcg with Pen B, depending on participant's dose of Insulin glargine on the day prior to randomization.
Dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L). Pen A was used for administration of doses up to 40 U/20 mcg and Pen B for administration of doses from 30 U/10 mcg up to 60 U/20 mcg.
Treatment: Drugs: Insulin glargine (HOE901)
Insulin glargine was self-administered QD by SC injection at approximately the same time every day.
After screening, eligible participants entered 6 week run-in phase during which they were switched (if necessary) to insulin glargine and dose was stabilized. The first dose after randomization was same as the one administered on the day prior to randomization and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L).
Treatment: Drugs: Metformin (Background Drug)
Pharmaceutical form: Tablet; Route of administration: Oral administration
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change in Glycated Hemoglobin (HbA1c) From Baseline to Week 30
Query!
Assessment method [1]
0
0
Change in HbA1c was calculated by subtracting baseline value from Week 30 value.
Query!
Timepoint [1]
0
0
Baseline, Week 30
Query!
Secondary outcome [1]
0
0
Percentage of Participants With HbA1c <7.0% or =6.5% at Week 30
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Week 30
Query!
Secondary outcome [2]
0
0
Change in 2-hour Plasma Blood Glucose Excursion From Baseline to Week 30
Query!
Assessment method [2]
0
0
Plasma glucose excursion = 2-hour postprandial glucose (PPG) minus plasma glucose value obtained 30 minutes prior to the start of the meal and before investigational medicinal product (IMP) administration, if IMP was injected before breakfast. Change in plasma glucose excursions was calculated by subtracting baseline value from Week 30 value.
Query!
Timepoint [2]
0
0
Baseline, Week 30
Query!
Secondary outcome [3]
0
0
Change in Body Weight From Baseline to Week 30
Query!
Assessment method [3]
0
0
Change in body weight was calculated by subtracting baseline value from Week 30 value.
Query!
Timepoint [3]
0
0
Baseline, Week 30
Query!
Secondary outcome [4]
0
0
Mean Change in 7-point Self-monitored Plasma Glucose (SMPG) Profile From Baseline to Week 30
Query!
Assessment method [4]
0
0
Participants recorded a 7-point plasma glucose profile measured before and 2-hours after each meal and at bedtime, two times in a week before baseline, before visit Week 12 and before visit Week 30 and the average value across the profiles performed in the week before a visit for the 7 time points was calculated. Change in average 7 point SMPG was calculated by subtracting baseline value from Week 30 value. The analysis included all scheduled measurements obtained during the study. The missing data was handled by mixed effect model with repeated measures (MMRM) approach.
Query!
Timepoint [4]
0
0
Baseline, Week 30
Query!
Secondary outcome [5]
0
0
Percentage of Participants Reaching HbA1c <7.0% With No Body Weight Gain at Week 30
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Week 30
Query!
Secondary outcome [6]
0
0
Change in Daily Insulin Glargine Dose From Baseline to Week 30
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Baseline, Week 30
Query!
Secondary outcome [7]
0
0
Percentage of Participants Reaching HbA1c <7.0% With No Body Weight Gain at Week 30 and No Documented Symptomatic Hypoglycemia (Plasma Glucose [PG] = 70 mg/dL [3.9 mmol/L]) During 30-Week Treatment Period
Query!
Assessment method [7]
0
0
Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of =70 mg/dL (3.9 mmol/L).
Query!
Timepoint [7]
0
0
Baseline up to Week 30
Query!
Secondary outcome [8]
0
0
Change in FPG From Baseline to Week 30
Query!
Assessment method [8]
0
0
Change in FPG was calculated by subtracting baseline value from Week 30 value.
Query!
Timepoint [8]
0
0
Baseline, Week 30
Query!
Secondary outcome [9]
0
0
Change in 2-hour PPG From Baseline to Week 30
Query!
Assessment method [9]
0
0
Change in PPG was calculated by subtracting baseline value from Week 30 value.
Query!
Timepoint [9]
0
0
Baseline, Week 30
Query!
Secondary outcome [10]
0
0
Percentage of Participants Reaching HbA1c <7.0% With No Documented Symptomatic Hypoglycemia (PG = 70 mg/dL [3.9 mmol/L]) During 30-Week Treatment Period
Query!
Assessment method [10]
0
0
Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of =70 mg/dL (3.9 mmol/L).
Query!
Timepoint [10]
0
0
Baseline up to Week 30
Query!
Secondary outcome [11]
0
0
Percentage of Participants Requiring Rescue Therapy During 30-Week Treatment Period
Query!
Assessment method [11]
0
0
Routine fasting SMPG and central laboratory FPG (and HbA1c after Week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after Week 12) were performed. Threshold values - from Week 8 to Week 12: fasting SMPG/FPG >240 mg/dL (13.3 mmol/L), and from Week 12 to Week 30: fasting SMPG/FPG >200 mg/dL (11.1 mmol/L) or HbA1c >8%.
Query!
Timepoint [11]
0
0
Baseline up to Week 30
Query!
Secondary outcome [12]
0
0
Number of Documented Symptomatic Hypoglycemia Events Per Subject-Year
Query!
Assessment method [12]
0
0
Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of =70 mg/dL (3.9 mmol/L).
Query!
Timepoint [12]
0
0
First dose of study drug up to 1 day after the last dose administration (median treatment exposure 211 days [FRC], 210 days [Insulin glargine])
Query!
Secondary outcome [13]
0
0
Percentage of Participants With Documented Symptomatic Hypoglycemia
Query!
Assessment method [13]
0
0
Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of =70 mg/dL (3.9 mmol/L).
Query!
Timepoint [13]
0
0
First dose of study drug up to 1 day after the last dose administration (median treatment exposure 211 days [FRC], 210 days [Insulin glargine])
Query!
Secondary outcome [14]
0
0
Percentage of Participants With Severe Symptomatic Hypoglycemia
Query!
Assessment method [14]
0
0
Severe symptomatic hypoglycemia was an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Plasma glucose measurements might not had been available during such an event, but neurological recovery attributable to the restoration of plasma glucose to normal was considered sufficient evidence that the event had been induced by a low plasma glucose concentration. Severe symptomatic hypoglycemia included all episodes in which neurological impairment was severe enough to prevent self-treatment, and which were thus thought to place participants at risk for injury to themselves or others.
Query!
Timepoint [14]
0
0
First dose of study drug up to 1 day after the last dose administration (median treatment exposure 211 days [FRC], 210 days [Insulin glargine])
Query!
Eligibility
Key inclusion criteria
Inclusion criteria :
- Type 2 diabetes mellitus diagnosed at least 1 year before the screening visit.
- Treatment with basal insulin for at least 6 months before the screening visit.
- Stable basal insulin regimen (i.e. type of insulin and time/frequency of the
injection) for at least 3 months before the screening visit.
- Stable (plus/minus 20 percent) total daily basal insulin dose between 15 and 40
Units/day for at least 2 months prior to the screening visit.
- For participants receiving basal insulin and 1 or 2 oral anti-diabetic drugs (OADs):
the OAD dose(s) must be stable during the 3 months before the screening visit. The
OADs could be 1 to 2 out of:
- metformin (more than or equal to 1500 mg/day or maximal tolerated dose),
- a sulfonylurea,
- a glinide,
- a dipeptidyl-peptidase-4 inhibitor,
- a sodium glucose co-transporter 2 inhibitor,
- Fasting Plasma Glucose (FPG) less than or equal to 180 mg/dL(10.0 mmol/L) at screening
visit for participants receiving basal insulin in combination with 2 OADs or with 1
OAD other than metformin; FPG less than or equal to 200 mg/dL (11.1 mmol/L) at
screening visit for participants on basal insulin only or basal insulin plus metformin
at screening visit.
- Signed written informed consent.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
- Age under legal age of adulthood at screening visit.
- HbA1c at screening visit less than 7.5% or above 10%.
- Pregnancy or lactation, women of childbearing potential with no effective
contraceptive method.
- Use of other oral or injectable glucose-lowering agents than stated in the inclusion
criteria in a period of 3 months prior to screening.
- Previous use of insulin other than basal insulin eg, prandial or pre-mixed insulin, in
the year prior to screening. Note: Short term treatment (=10 days) due to intercurrent
illness is allowed.
- History discontinuation of a previous treatment with Glucagon Like Peptide -1 Receptor
Agonists for safety/tolerability or lack of efficacy.
- Participant who had previously participated in any clinical trial with lixisenatide or
the insulin glargine/lixisenatide FRC or had previously received lixisenatide.
- Use of weight loss drugs within 3 months prior to screening visit.
- Within the last 6 months prior to screening visit: history of stroke, myocardial
infarction, unstable angina, or heart failure requiring hospitalization. Planned
coronary, carotid or peripheral artery revascularisation procedures to be performed
during the study period.
- History of pancreatitis (unless pancreatitis was related to gallstones and
cholecystectomy was already performed), chronic pancreatitis, pancreatitis during a
previous treatment with incretin therapies, pancreatectomy, stomach/gastric surgery.
- Personal or immediate family history of medullary thyroid cancer (MTC) or genetic
conditions that predispose to MTC (eg, multiple endocrine neoplasia syndromes).
- Uncontrolled or inadequately controlled hypertension (systolic blood pressure above
180 mmHg or diastolic blood pressure above 95 mmHg) at screening visit.
- At screening visit, Body Mass Index (BMI) less than or equal to 20 or above 40 kg/m^2.
- At screening visit amylase and/or lipase more than 3 times the upper limit of the
normal (ULN) laboratory range.
- At screening visit alanine aminotransferase (ALT) or alkaline phosphatase (AST) more
than 3 ULN.
- At screening visit calcitonin above or equal to 20 pg/mL (5.9 pmol/L).
- Any contraindication to metformin use, according to local labeling, if the participant
was taking metformin.
- Participant who had a renal function impairment with creatinine clearance less than 30
mL/min (using the Cockcroft and Gault formula) or end-stage renal disease for
participants, not treated with metformin.
Exclusion criteria for randomization:
- HbA1c less than 7% or above 10% .
- Mean fasting SMPG calculated from the self-measurements for 7 days the week before
randomization visit was above 140 mg/dL (7.8 mmol/L).
- Average insulin glargine daily dose less than 20 Units or above 50 Units (in the week
before randomization visit).
- Amylase and/or lipase more than 3 ULN .
The above information is not intended to contain all considerations relevant to a
participant's potential participation in a clinical trial.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/01/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/07/2015
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
736
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Investigational Site Number 036505 - Box Hill
Query!
Recruitment hospital [2]
0
0
Investigational Site Number 036501 - Heidelberg
Query!
Recruitment hospital [3]
0
0
Investigational Site Number 036504 - Parkville
Query!
Recruitment postcode(s) [1]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [2]
0
0
3081 - Heidelberg
Query!
Recruitment postcode(s) [3]
0
0
3050 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Delaware
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Georgia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Idaho
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Illinois
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Indiana
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Kentucky
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Maine
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Maryland
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Michigan
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Minnesota
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Montana
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Nebraska
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Nevada
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
New Hampshire
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
New Mexico
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
New York
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
North Carolina
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Ohio
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Oregon
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Pennsylvania
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
South Carolina
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
South Dakota
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Texas
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Utah
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Vermont
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Virginia
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Washington
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
Wisconsin
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Beamsville
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Brampton
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Guelph
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
Kelowna
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
Montreal
Query!
Country [40]
0
0
Canada
Query!
State/province [40]
0
0
Oakville
Query!
Country [41]
0
0
Canada
Query!
State/province [41]
0
0
St-Romuald
Query!
Country [42]
0
0
Canada
Query!
State/province [42]
0
0
Toronto
Query!
Country [43]
0
0
Canada
Query!
State/province [43]
0
0
Vancouver
Query!
Country [44]
0
0
Canada
Query!
State/province [44]
0
0
Victoria
Query!
Country [45]
0
0
Chile
Query!
State/province [45]
0
0
Puerto Varas
Query!
Country [46]
0
0
Chile
Query!
State/province [46]
0
0
Santiago
Query!
Country [47]
0
0
Chile
Query!
State/province [47]
0
0
Talagante
Query!
Country [48]
0
0
Chile
Query!
State/province [48]
0
0
Temuco
Query!
Country [49]
0
0
Chile
Query!
State/province [49]
0
0
Vina Del Mar
Query!
Country [50]
0
0
Czech Republic
Query!
State/province [50]
0
0
Cheb
Query!
Country [51]
0
0
Czech Republic
Query!
State/province [51]
0
0
Hranice
Query!
Country [52]
0
0
Czech Republic
Query!
State/province [52]
0
0
Krnov
Query!
Country [53]
0
0
Czech Republic
Query!
State/province [53]
0
0
Liberec
Query!
Country [54]
0
0
Czech Republic
Query!
State/province [54]
0
0
Olomouc
Query!
Country [55]
0
0
Czech Republic
Query!
State/province [55]
0
0
Plzen
Query!
Country [56]
0
0
Czech Republic
Query!
State/province [56]
0
0
Praha 4
Query!
Country [57]
0
0
Czech Republic
Query!
State/province [57]
0
0
Praha 5
Query!
Country [58]
0
0
Czech Republic
Query!
State/province [58]
0
0
Praha 8
Query!
Country [59]
0
0
Czech Republic
Query!
State/province [59]
0
0
Prostejov
Query!
Country [60]
0
0
Denmark
Query!
State/province [60]
0
0
Aarhus C
Query!
Country [61]
0
0
Denmark
Query!
State/province [61]
0
0
Horsens
Query!
Country [62]
0
0
Denmark
Query!
State/province [62]
0
0
Kolding
Query!
Country [63]
0
0
Denmark
Query!
State/province [63]
0
0
København Nv
Query!
Country [64]
0
0
Denmark
Query!
State/province [64]
0
0
København S
Query!
Country [65]
0
0
Denmark
Query!
State/province [65]
0
0
Viborg
Query!
Country [66]
0
0
Estonia
Query!
State/province [66]
0
0
Pärnu
Query!
Country [67]
0
0
Estonia
Query!
State/province [67]
0
0
Tallinn
Query!
Country [68]
0
0
Estonia
Query!
State/province [68]
0
0
Tartu
Query!
Country [69]
0
0
Hungary
Query!
State/province [69]
0
0
Budapest
Query!
Country [70]
0
0
Hungary
Query!
State/province [70]
0
0
Debrecen
Query!
Country [71]
0
0
Hungary
Query!
State/province [71]
0
0
Kaposvár
Query!
Country [72]
0
0
Hungary
Query!
State/province [72]
0
0
Pápa
Query!
Country [73]
0
0
Lithuania
Query!
State/province [73]
0
0
Kaunas
Query!
Country [74]
0
0
Lithuania
Query!
State/province [74]
0
0
Kedainiai
Query!
Country [75]
0
0
Lithuania
Query!
State/province [75]
0
0
Klaipeda
Query!
Country [76]
0
0
Lithuania
Query!
State/province [76]
0
0
Vilnius
Query!
Country [77]
0
0
Mexico
Query!
State/province [77]
0
0
Celaya
Query!
Country [78]
0
0
Mexico
Query!
State/province [78]
0
0
Cuernavaca
Query!
Country [79]
0
0
Mexico
Query!
State/province [79]
0
0
Guadalajara
Query!
Country [80]
0
0
Mexico
Query!
State/province [80]
0
0
México
Query!
Country [81]
0
0
Mexico
Query!
State/province [81]
0
0
Pachuca
Query!
Country [82]
0
0
Mexico
Query!
State/province [82]
0
0
Puebla
Query!
Country [83]
0
0
Netherlands
Query!
State/province [83]
0
0
Almere
Query!
Country [84]
0
0
Poland
Query!
State/province [84]
0
0
Bialystok
Query!
Country [85]
0
0
Poland
Query!
State/province [85]
0
0
Krakow
Query!
Country [86]
0
0
Poland
Query!
State/province [86]
0
0
Plock
Query!
Country [87]
0
0
Poland
Query!
State/province [87]
0
0
Szczecin
Query!
Country [88]
0
0
Poland
Query!
State/province [88]
0
0
Warszawa
Query!
Country [89]
0
0
Romania
Query!
State/province [89]
0
0
Brasov
Query!
Country [90]
0
0
Romania
Query!
State/province [90]
0
0
Bucharest
Query!
Country [91]
0
0
Romania
Query!
State/province [91]
0
0
Bucuresti
Query!
Country [92]
0
0
Romania
Query!
State/province [92]
0
0
Hunedoara
Query!
Country [93]
0
0
Romania
Query!
State/province [93]
0
0
Iasi
Query!
Country [94]
0
0
Romania
Query!
State/province [94]
0
0
Oradea
Query!
Country [95]
0
0
Romania
Query!
State/province [95]
0
0
Sibiu
Query!
Country [96]
0
0
Romania
Query!
State/province [96]
0
0
Targu Mures
Query!
Country [97]
0
0
Romania
Query!
State/province [97]
0
0
Timisoara
Query!
Country [98]
0
0
Russian Federation
Query!
State/province [98]
0
0
Arkhangelsk
Query!
Country [99]
0
0
Russian Federation
Query!
State/province [99]
0
0
Moscow
Query!
Country [100]
0
0
Russian Federation
Query!
State/province [100]
0
0
Penza
Query!
Country [101]
0
0
Russian Federation
Query!
State/province [101]
0
0
Saint-Petersburg
Query!
Country [102]
0
0
Russian Federation
Query!
State/province [102]
0
0
Samara
Query!
Country [103]
0
0
Russian Federation
Query!
State/province [103]
0
0
Saratov
Query!
Country [104]
0
0
Russian Federation
Query!
State/province [104]
0
0
St-Petersburg
Query!
Country [105]
0
0
Russian Federation
Query!
State/province [105]
0
0
St. Petersburg
Query!
Country [106]
0
0
Russian Federation
Query!
State/province [106]
0
0
Voronezh
Query!
Country [107]
0
0
Slovakia
Query!
State/province [107]
0
0
Bratislava
Query!
Country [108]
0
0
Slovakia
Query!
State/province [108]
0
0
Bytca
Query!
Country [109]
0
0
Slovakia
Query!
State/province [109]
0
0
Kosice
Query!
Country [110]
0
0
Slovakia
Query!
State/province [110]
0
0
Lubochna
Query!
Country [111]
0
0
Slovakia
Query!
State/province [111]
0
0
Moldava Nad Bodvou
Query!
Country [112]
0
0
Slovakia
Query!
State/province [112]
0
0
Nove Mesto Nad Vahom
Query!
Country [113]
0
0
Slovakia
Query!
State/province [113]
0
0
Nove Zamky
Query!
Country [114]
0
0
Slovakia
Query!
State/province [114]
0
0
Trnava
Query!
Country [115]
0
0
Slovakia
Query!
State/province [115]
0
0
Zilina
Query!
Country [116]
0
0
Spain
Query!
State/province [116]
0
0
Alicante
Query!
Country [117]
0
0
Spain
Query!
State/province [117]
0
0
Alzira
Query!
Country [118]
0
0
Spain
Query!
State/province [118]
0
0
Barcelona
Query!
Country [119]
0
0
Spain
Query!
State/province [119]
0
0
Cáceres
Query!
Country [120]
0
0
Spain
Query!
State/province [120]
0
0
El Ferrol
Query!
Country [121]
0
0
Spain
Query!
State/province [121]
0
0
La Coruña
Query!
Country [122]
0
0
Spain
Query!
State/province [122]
0
0
Sabadell
Query!
Country [123]
0
0
Spain
Query!
State/province [123]
0
0
Segovia
Query!
Country [124]
0
0
Spain
Query!
State/province [124]
0
0
Valencia
Query!
Country [125]
0
0
Sweden
Query!
State/province [125]
0
0
Ljungby
Query!
Country [126]
0
0
Sweden
Query!
State/province [126]
0
0
Malmö
Query!
Country [127]
0
0
Sweden
Query!
State/province [127]
0
0
Rättvik
Query!
Country [128]
0
0
Sweden
Query!
State/province [128]
0
0
Stenungssund
Query!
Country [129]
0
0
Sweden
Query!
State/province [129]
0
0
Stockholm
Query!
Country [130]
0
0
Sweden
Query!
State/province [130]
0
0
Vällingby
Query!
Country [131]
0
0
Ukraine
Query!
State/province [131]
0
0
Chernivtsi
Query!
Country [132]
0
0
Ukraine
Query!
State/province [132]
0
0
Kyiv
Query!
Country [133]
0
0
Ukraine
Query!
State/province [133]
0
0
Lviv
Query!
Country [134]
0
0
Ukraine
Query!
State/province [134]
0
0
Vinnytsya
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Sanofi
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Primary Objective:
To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination
(FRC) to insulin glargine in glycated hemoglobin (HbA1c) change from baseline to Week 30.
Secondary Objective:
To compare the overall efficacy and safety of insulin glargine/lixisenatide FRC to insulin
glargine (with or without metformin) over a 30 week treatment period in participants with
type 2 diabetes.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02058160
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Sciences & Operations
Query!
Address
0
0
Sanofi
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02058160
Download to PDF